Mutant NPM1 Maintains the Leukemic State through HOX Expression - ScienceDirect
Frontiers | Small Molecule Inhibitors of CRM1
Vorinostat | C14H20N2O3 | CID 5311 - PubChem
Mutant NPM1 Maintains the Leukemic State through HOX Expression - ScienceDirect
Oral Selinxor – First-In-Class Anti-Cancer Agent
XPO1/CRM1 is a promising prognostic indicator for neuroblastoma and represented a therapeutic target by selective inhibitor verdinexor | Journal of Experimental & Clinical Cancer Research | Full Text
Frontiers | Ciltacabtagene autoleucel: The second anti-BCMA CAR T-cell therapeutic armamentarium of relapsed or refractory multiple myeloma
Frontiers | CRM1 Inhibitors for Antiviral Therapy
Atomic basis of CRM1-cargo recognition, release and inhibition. - Abstract - Europe PMC
CovBinderInPDB: A Structure-Based Covalent Binder Database | Journal of Chemical Information and Modeling
XPO1/CRM1 is a promising prognostic indicator for neuroblastoma and represented a therapeutic target by selective inhibitor verdinexor | Journal of Experimental & Clinical Cancer Research | Full Text
Mutant NPM1 Maintains the Leukemic State through HOX Expression
SBGrid Consortium - Tales - Yuh Min Chook - University of Texas Southwestern Medical Center
The Bruton tyrosine kinase inhibitor zanubrutinib (BGB-3111) demonstrated synergies with other anti-lymphoma targeted agents | Haematologica
PDF) Drugs used in Italy against Covid-19
Consensus model: average of GSE(Φ,B) and ABSOLV model predictions... | Download Scientific Diagram
XPO1/CRM1 is a promising prognostic indicator for neuroblastoma and represented a therapeutic target by selective inhibitor verdinexor | Journal of Experimental & Clinical Cancer Research | Full Text
Bortezomib | C19H25BN4O4 | CID 387447 - PubChem
Selinexor - Wikipedia
Researchers discover genes that predict good response to blood cancer therapy
Once-per-week selinexor, bortezomib, and dexamethasone versus twice-per-week bortezomib and dexamethasone in patients with multiple myeloma (BOSTON): a randomised, open-label, phase 3 trial
Pharmaceuticals | Free Full-Text | Technologies for Direct Detection of Covalent Protein–Drug Adducts
News - Biocon
SBGrid Consortium - Tales - Yuh Min Chook - University of Texas Southwestern Medical Center
Cells | Free Full-Text | CellMAPtracer: A User-Friendly Tracking Tool for Long-Term Migratory and Proliferating Cells Associated with FUCCI Systems
